Liposomal Irinotecan and Apatinib in ES-SCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Liposomal Irinotecan and Apatinib in ES-SCLC — Stella

Recruiting

Back to Small Cell Lung Cancer Extensive Stage trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang

Key details

Phase

Safety & dosing

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment target

~30 participants

Started

December 2024

Primary completion

December 2027

Age range

18 Years – 75 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov